Fast and reliable
The new diabetes drug is more effective by all criteria than the existing ones
Svetlana Maslova, Hi-tech+
Scientists have presented new results of clinical trials of the recently approved drug tirzepatide, developed for the treatment of type 2 diabetes mellitus. Compared to the medications available today, it reduces blood glucose levels and weight of patients more effectively, quickly reaching targets. Such a strategy should ensure successful prevention of diabetes complications, the authors hope.
In May of this year, the United States approved the injectable drug Mounjaro (tirzepatide) for the treatment of type 2 diabetes mellitus in adults. The introduction of the drug into clinical practice is based on the impressive results achieved by patients during treatment with tirzepatide compared to other medications. Now scientists have presented new data on the effectiveness of tirzepatide, writes EurekAlert.
Comparing tirzepatide with existing drugs today, semaglutide and insulin, scientists have found that it reaches its targets faster — it reduces weight and glucose (glycated hemoglobin) levels in the blood. Different dosages were evaluated: 5, 10 and 15 mg.
Tirzepatide reached the required indicators about 4 weeks earlier than semaglutide and 4-12 weeks earlier than insulin. So far, this is the best data available at the moment, the authors specify.
As is known, higher levels of glycated hemoglobin are associated with the development of complications on the heart, kidneys, eyes and nervous system. Scientists expect that the use of tirzepatide in clinical practice will reduce the risks of these complications in the long term.
"Tirzepatide is unique in that it mimics the action of two natural hormones that release insulin and suppress appetite in one injection," explained study author Adi Viljoen. We are talking about the hormone glucagon-like peptide-1 (GLP-1) and the hormone glucose-dependent insulinotropic polypeptide (GIP).
It is worth clarifying that taking tirzepatide, like any other drugs for the treatment of diabetes, involves a change in eating habits and physical activity. Today, more than 400 million people in the world live with type 2 diabetes. It is likely that the results of the evaluation of tirzepatide will have global significance for the health of these patients in the coming years.
Portal "Eternal youth" http://vechnayamolodost.ru